Growth-hormone-releasing Hormone as a Prognostic Biomarker and Therapeutic Target in Gastrointestinal Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jemal A.; Bray F.; Center M.M.; Ferlay J.; Ward E.; Forman D.; Global cancer statistics. CA Cancer J Clin 2011,61(2),69-90
Kobayashi H.; Enomoto A.; Woods S.L.; Burt A.D.; Takahashi M.; Worthley D.L.; Cancer-associated fibroblasts in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol 2019,16(5),282-295
Kiaris H.; Chatzistamou I.; Papavassiliou A.G.; Schally A.V.; Growth hormone-releasing hormone: Not only a neurohormone. Trends Endocrinol Metab 2011,22(8),311-317
Barabutis N.; Schally A.V.; Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology. Cell Cycle 2010,9(20),4110-4116
Barabutis N.; Schally A.V.; Siejka A.; P53, GHRH, inflammation and cancer. EBioMedicine 2018,37,557-562
Bellyei S.; Schally A.V.; Zarandi M.; Varga J.L.; Vidaurre I.; Pozsgai E.; GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett 2010,293(1),31-40
Muñoz-Moreno L.; Carmena M.J.; Schally A.V.; Prieto J.C.; Bajo A.M.; Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists. Invest New Drugs 2020,38(3),746-754
Hohla F.; Buchholz S.; Schally A.V.; Seitz S.; Rick F.G.; Szalontay L.; Varga J.L.; Zarandi M.; Halmos G.; Vidaurre I.; Krishan A.; Kurtoglu M.; Chandna S.; Aigner E.; Datz C.; GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 2009,8(19),3149-3156
Busto R.; Schally A.V.; Varga J.L.; Garcia-Fernandez M.O.; Groot K.; Armatis P.; Szepeshazi K.; The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 2002,99(18),11866-11871
Doga M.; Bonadonna S.; Burattin A.; Giustina A.; Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: Relevant clinical aspects. Ann Oncol 2001,12(Suppl. 2),S89-S94
Siejka A.; Barabutis N.; Schally A.V.; GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle 2011,10(21),3714-3718
Mayo K.E.; Miller T.; DeAlmeida V.; Godfrey P.; Zheng J.; Cunha S.R.; Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 2000,55,237-266
Lin-Su K.; Wajnrajch M.P.; Growth hormone releasing hormone (GHRH) and the GHRH receptor. Rev Endocr Metab Disord 2002,3(4),313-323
Uddin M.A.; Akhter M.S.; Singh S.S.; Kubra K.T.; Schally A.V.; Jois S.; Barabutis N.; GHRH antagonists support lung endothelial barrier function. Tissue Barriers 2019,7(4),1669989
Veldhuis J.; Pulsatile hormone secretion: Mechanisms, significance and evaluation. Ultradian Rhythms from Molecules to Mind 2008,229-248
Olarescu N.C.; Gunawardane K.; Hansen T.K.; Møller N.; Jørgensen J.O.L.; Normal physiology of growth hormone in adults; Endotext, Available form: 2019
Ludwig B.; Ziegler C.G.; Schally A.V.; Richter C.; Steffen A.; Jabs N.; Funk R.H.; Brendel M.D.; Block N.L.; Ehrhart-Bornstein M.; Bornstein S.R.; Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci USA 2010,107(28),12623-12628
Rick F.G.; Seitz S.; Schally A.V.; Szalontay L.; Krishan A.; Datz C.; Stadlmayr A.; Buchholz S.; Block N.L.; Hohla F.; GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle 2012,11(22),4203-4210
Schally A.V.; Perez R.; Block N.L.; Rick F.G.; Potentiating effects of GHRH analogs on the response to chemotherapy. Cell Cycle 2015,14(5),699-704
Muñoz-Moreno L.; Arenas M.I.; Carmena M.J.; Schally A.V.; Sánchez-Chapado M.; Prieto J.C.; Bajo A.M.; Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer. Oncotarget 2016,7(32),52195-52206
Bodart G.; Goffinet L.; Morrhaye G.; Farhat K.; de Saint-Hubert M.; Debacq-Chainiaux F.; Swine C.; Geenen V.; Martens H.J.; Somatotrope GHRH/GH/IGF-1 axis at the crossroads between immunosenescence and frailty. Ann N Y Acad Sci 2015,1351(1),61-67
Kahán Z.; Arencibia J.M.; Csernus V.J.; Groot K.; Kineman R.D.; Robinson W.R.; Schally A.V.; Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 1999,84(2),582-589
Guo J.; Schally A.V.; Zarandi M.; Varga J.; Leung P.C.K.; Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol 2010,8(1),54
Cui T.; Schally A.V.; Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1. Oncotarget 2018,9(47),28745-28756
Chopin L.K.; Herington A.C.; A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 2001,49(2),116-121
Stępień T.; Sacewicz M.; Ławnicka H.; Krupiński R.; Komorowski J.; Siejka A.; Stępień H.; Stimulatory effect of growth hormone–releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. Neuropeptides 2009,43(5),397-400
Hohla F.; Moder A.; Mayrhauser U.; Hauser-Kronberger C.; Schally A.; Varga J.; Zarandi M.; Buchholz S.; Huber R.; Aigner E.; Ritter M.; Datz C.; Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. Int J Oncol 2008,33(1),137-143
Kovács M.; Schally A.V.; Hohla F.; Rick F.G.; Pozsgai É.; Szalontay L.; Varga J.L.; Zarándi M.; A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides 2010,31(10),1839-1846
Csernus V.J.; Schally A.V.; Kiaris H.; Armatis P.; Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 1999,96(6),3098-3103
Zhang H.; Kong Q.; Wang J.; Jiang Y.; Hua H.; Complex roles of cAMP–PKA–CREB signaling in cancer. Exp Hematol Oncol 2020,9(1),32
Hohla F.; Schally A.V.; Szepeshazi K.; Varga J.L.; Buchholz S.; Köster F.; Heinrich E.; Halmos G.; Rick F.G.; Kannadka C.; Datz C.; Kanashiro C.A.; Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci USA 2006,103(39),14513-14518
Rick F.G.; Schally A.V.; Szalontay L.; Block N.L.; Szepeshazi K.; Nadji M.; Zarandi M.; Hohla F.; Buchholz S.; Seitz S.; Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA 2012,109(5),1655-1660
Martari M.; Salvatori R.; Diseases associated with growth hormone-releasing hormone receptor (GHRHR) mutations. Prog Mol Biol Transl Sci 2009,88,57-84
Sacewicz M.; Ławnicka H.; Siejka A.; Stępień T.; Krupiński R.; Komorowski J.; Stępień H.; Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro. Cancer Lett 2008,268(1),120-128
Muñoz-Moreno L.; Bajo A.M.; Prieto J.C.; Carmena M.J.; Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells. Mol Cell Endocrinol 2017,446,59-69
Kanashiro C.; Schally A.; Zarandi M.; Hammann B.; Varga J.; Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol 2007,30(4),1019-1028
Chen H.H.W.; Kuo M.T.; Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget 2017,8(37),62742-62758
Fahrenholtz C.D.; Rick F.G.; Garcia M.I.; Zarandi M.; Cai R.Z.; Block N.L.; Schally A.V.; Burnstein K.L.; Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci USA 2014,111(3),1084-1089
Villanova T.; Gesmundo I.; Audrito V.; Vitale N.; Silvagno F.; Musuraca C.; Righi L.; Libener R.; Riganti C.; Bironzo P.; Deaglio S.; Papotti M.; Cai R.; Sha W.; Ghigo E.; Schally A.V.; Granata R.; Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proc Natl Acad Sci USA 2019,116(6),2226-2231
Gesmundo I.; Dematteis A.; Fanciulli A.; Romana G.F.; Cai R.; Sha W.; Growth hormone-releasing hormone (GHRH) antagonists increase the sensitivity to radiotherapy in lung cancer cells. Endocrine Abstracts Available form: 2020
Ogilvy-Stuart A.L.; Stirling H.F.; Kelnar C.J.H.; Savage M.O.; Dunger D.B.; Buckler J.M.H.; Shalet S.M.; Treatment of radiation‐induced growth hormone deficiency with growth hormone‐releasing hormone. Clin Endocrinol (Oxf) 1997,46(5),571-578
Paris F.; Fuks Z.; Kang A.; Capodieci P.; Juan G.; Ehleiter D.; Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001,293,293-297
Seitz S.; Rick F.G.; Schally A.V.; Treszl A.; Hohla F.; Szalontay L.; Zarandi M.; Ortmann O.; Engel J.B.; Buchholz S.; Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncol Rep 2013,30(1),413-418
Muñoz-Moreno L.; Arenas M.I.; Schally A.V.; Fernández-Martínez A.B.; Zarka E.; González-Santander M.; Carmena M.J.; Vacas E.; Prieto J.C.; Bajo A.M.; Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer. Int J Cancer 2013,132(4),755-765
Engel J.; Schally A.; Varga J.; Halmos G.; Buchholz S.; GHRH-antagonist in combination with docetaxel chemotherapy induces regression of MX-1 human experimental breast cancers. Cancer Res 2007,67(9)(Suppl.),3568
Seitz S.; Schally A.V.; Papadia A.; Rick F.G.; Szlatonay L.; Ortmann O.; Engel J.; Köster F.; Buchholz S.; 0141 Combination of antagonists of growth hormone-releasing hormone with docetaxel as potential therapy in breast cancer in a preclinical study. Breast 2009,18,S54
Buchholz S.; Schally A.V.; Engel J.B.; Hohla F.; Heinrich E.; Koester F.; Varga J.L.; Halmos G.; Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 2007,104(6),1943-1946
Jaszberenyi M.; Rick F.G.; Popovics P.; Block N.L.; Zarandi M.; Cai R.Z.; Vidaurre I.; Szalontay L.; Jayakumar A.R.; Schally A.V.; Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proc Natl Acad Sci USA 2014,111(2),781-786
Huang W.C.; Hung M.C.; Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009,108(3),180-194
Leone S.; Chiavaroli A.; Recinella L.; Di Valerio V.; Veschi S.; Gasparo I.; Bitto A.; Ferrante C.; Orlando G.; Salvatori R.; Brunetti L.; Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis. Pharmacol Res 2020,152,104614
Theophanous E.; Petraki C.; Scorilas A.; Komborozos V.; Veloudis G.; Varga J.L.; Zarandi M.; Schally A.V.; Koutsilieris M.; The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. Mol Med 2009,15(7-8),242-247
Gan J.; Ke X.; Jiang J.; Dong H.; Yao Z.; Lin Y.; Lin W.; Wu X.; Yan S.; Zhuang Y.; Chu W.K.; Cai R.; Zhang X.; Cheung H.S.; Block N.L.; Pang C.P.; Schally A.V.; Zhang H.; Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1–STAT3/NF-κB signaling. Proc Natl Acad Sci USA 2016,113(51),14745-14750
Mezey G.; Treszl A.; Schally A.V.; Block N.L.; Vízkeleti L.; Juhász A.; Klekner Á.; Nagy J.; Balázs M.; Halmos G.; Bognár L.; Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes. J Cancer Res Clin Oncol 2014,140(10),1641-1649
Cai R.; Zhang X.; Wang H.; Cui T.; Halmos G.; Sha W.; He J.; Popovics P.; Vidaurre I.; Zhang C.; Mirsaeidi M.; Schally A.V.; Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides 2022,150,170716
Klukovits A.; Schally A.V.; Szalontay L.; Vidaurre I.; Papadia A.; Zarandi M.; Varga J.L.; Block N.L.; Halmos G.; Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer 2012,118(3),670-680
Szepeshazi K.; Schally A.V.; Groot K.; Armatis P.; Halmos G.; Herbert F.; Szende B.; Varga J.L.; Zarandi M.; Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 2000,82(10),1724-1731
Recinella L.; Chiavaroli A.; Veschi S.; Di Valerio V.; Lattanzio R.; Orlando G.; Ferrante C.; Gesmundo I.; Granata R.; Cai R.; Sha W.; Schally A.V.; Brunetti L.; Leone S.; Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice. Biomed Pharmacother 2022,146,112554
Barabutis N.; Siejka A.; The highly interrelated GHRH, p53, and Hsp90 universe. Cell Biol Int 2020,44(8),1558-1563
Rick F.G.; Buchholz S.; Schally A.V.; Szalontay L.; Krishan A.; Datz C.; Stadlmayr A.; Aigner E.; Perez R.; Seitz S.; Block N.L.; Hohla F.; Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle 2012,11(13),2518-2525
Gesmundo I.; Granato G.; Fuentes-Fayos A.C.; Alvarez C.V.; Dieguez C.; Zatelli M.C.; Congiusta N.; Banfi D.; Prencipe N.; Leone S.; Brunetti L.; Castaño J.P.; Luque R.M.; Cai R.; Sha W.; Ghigo E.; Schally A.V.; Granata R.; Antagonists of growth hormone-releasing hormone inhibit the growth of pituitary adenoma cells by hampering oncogenic pathways and promoting apoptotic signaling. Cancers (Basel) 2021,13(16),3950
Lamharzi N.; Schally A.V.; Koppán M.; Groot K.; Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 1998,95(15),8864-8868